eviti, Inc. to Introduce Quicker, More Intuitive Oncology Decision-Support Platform in eviti 4.0

eviti, Inc. to Introduce Quicker, More Intuitive Oncology Decision-Support Platform in eviti 4.0

eviti, Inc.Traci Boehringer, 215-569-0656, ext. 196

eviti, Inc., an independent health information technology and company, to demonstrate new, more powerful version of its market leading decision-support platform in booth 4044 at the 2013 ASCO Annual Meeting, with general availability during July 2013. The latest version known as eviti 4.0 introduces workflow enhancements, along with greater ease of search, and new functionality for practice-wide preferences that are expected to reduce data entry time for practice staff by up to 50%, and increase eviti code automation rates by 300%, all without compromising quality or clinical integrity.

eviti|Advisor, the decision-support component, will feature instant search results capability. Providers will simply select a cancer type from the drop down menu, and all regimens for the cancer type will instantly appear. Providers will be able to easily add filters to refine results. This instant search results capability will complement eviti’s exclusive regimen comparison feature that allows providers to compare regimens side-by-side based on expected clinical outcomes, costs and toxicities, a feature that helps facilitate shared decision-making with patients.

New in eviti 4.0, eviti|Advisor Enterprise Edition will assist practice administrators in ensuring the prescription of quality care through systematic oversight and management of treatment selection across all providers and practice locations. eviti|Advisor Enterprise Edition will allow configuration of practice-preferred regimens that will appear first in the list of evidence-based treatments for each cancer type. In addition, it will allow easy identification of available clinical trials at the practice site by filtering trial results by location.

Users of eviti|Connect, the pre-authorization component, will notice a significant decrease in the time required to obtain an eviti code, along with a more intuitive user experience. On average, users will see a decrease in the number of treatment plans requiring medical office review or peer-to-peer collaboration, with more plans receiving an automated eviti code.

eviti, Inc. CEO and President, Eduardo Beruff said, “In the past two and a half years since we introduced eviti to the marketplace, over half of all oncology practices in the U.S. have used eviti. The enhancements in eviti 4.0 are a direct result of vital user feedback combined with more powerful technology. With eviti, physicians can determine the most appropriate treatment for each patient, and patients are assured of optimal care for their specific cancer.”

Meeting attendees can visit the eviti booth (4044) for a demonstration of eviti 4.0.

About eviti, Inc.

eviti, Inc. is a leading health information technology and clinical decision-support company delivering solutions to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.

eviti’s growing national prominence is evidenced by the 2,700+ practices already registered to use the eviti platform. eviti’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world’s leading sources. eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit .